INFORMATION CONCERNING A NEW STUDY FOR ALPHA1-ANTITRYPSIN DEFICIENCY AND EMPHYSEMA IN WESTERN CANADA
DO YOU HAVE EMPHYSEMA WITH SEVERE ALPHA 1 -ANTITRYPSIN DEFICIENCY?
Dr. Abboud, Respiratory (LUNG) Specialist is conducting a Clinical Research Trial of an inhaled purified alpha-1 antitrypsin preparation given twice daily by nebuliser (a machine producing a mist of the medication for inhalation over a period of 15 minutes for each treatment) for a period of 50 weeks.
This is a double blind randomised trial, which means that half the subjects will get active medication and half will get a solution without any active medication (placebo). The choice will made by computer by chance (like flipping a coin), and neither the subject nor study staff will know what is being given.
There will be a total of 10 visits over a period of about 56 weeks, and breathing tests and blood samples will be obtained 7 times during the study .The advantage of the nebulizer treatment compared to the intravenous treatment with purified antitrypsin is that it may allow direct access of the antitrypsin to the lung at a lower dose and a lower cost than with intravenous infusion, and may be more convenient to the subject being treated.
To qualify, you must:
- Have severe alpha 1- antitrypsin deficiency and emphysema
- Have stopped smoking completely for at least one year
- Have no other serious disease or health problem
For more information, please contact Dr. R. Abboud’s Research Coordinator Jayamarx (Marx) at Dr. Abboud’s Clinical Trial Centre in the Seymour Health Centre at 604-678-8136, Cell phone 778-882-0779